todd manning

1. ABBVIE: A NEW PLAYER
IN ONCOLOGY
Todd Manning
General Manager, AbbVie Ltd

2. “The AbbVie oncology products
are all investigational in nature
and are currently not licensed
in any country. The ultimate
licensing of these compounds is
subject to regulatory review
and approval.”
2

3. AbbVie Oncology Vision
We will accomplish this by:
• Leveraging our leading-edge platforms
• Working closely with academia, diagnostic companies and cooperative
groups
• Bringing to market novel therapeutics with transformational increases in
efficacy and safety
Transform the Lives of
People with Cancer
It starts with science…
…and continues with AbbVie’s commitment to research and development
3

4.  Oncology is a new focus for AbbVie
 AbbVie has a rich oncology pipeline in more than 15 different tumour types
AbbVie’s late phase pipeline includes treatments for both haematological
malignancies and solid tumours
4
Phase 1
7 molecules
Phase 2
1 molecule
Phase 3
3 molecules
PARP inhibitor
(solid tumours)
potential
indications6
Phase 2/3 trials19
BCL-2 inhibitor
(haem malignancies)
potential
indications6
Phase 2/3 trials7
EGFR ADC
(glioblastoma)
potential
indications2
Phase 2/3 trials2
PI3K inhibitor
(haem malignancies)
potential
indications6
Phase 2/3 trials10

5. 5
Global Trials in Solid Tumours
 Brain Metastases  Breast
 NSCLC  SCLC
 Colorectal  Ovarian
 Gastric  Glioblastoma
In 2014 -
• ~1100 subjects enrolled in Phase 1-3 trials
• ~60 trials performed across multiple tumours
• Studies conducted in 44 countries
AbbVie’s oncology clinical development is founded on deep scientific and clinical
expertise
Global Trials in Haem. Malignancies
 Acute Myelogenous Leukemia
 Chronic Lymphocytic Leukemia
 Multiple Myeloma
 Non-Hodgkin’s Lymphoma
Current Trials in Ireland
 Squamous non-small cell lung cancer
 Glioblastoma

6. Manufacturing in Ireland: 2 of AbbVie’s 3 oncology compounds in phase 3
trials are manufactured in Ireland
• Each of the uniquely focused sites in
Ireland manufactures portions of
AbbVie’s top 20 products
• The company has 12 sites in total across
the United States, Europe and Puerto
Rico, as well as strategic partnerships
with third-party manufacturers
• Of the 3 oncology compounds in phase 3
trials, 2 are manufactured in Ireland
6

7. In addition to organic development of new compounds, AbbVie is also
investing heavily in the oncology pipeline
7

8. Summary
• AbbVie is new to oncology, and has a
number of compounds in pre-clinical,
early phase and late phase development
• Late phase trials include both solid
tumours and haematological
malignancies, and enrolled over 1100
patients in 2014
• AbbVie is investing in acquisitions and
licensing compounds, in addition to the
discovery and development process
8